Transcriptomics

Dataset Information

0

Oncogenic KRAS drives lipo-fibrogenesis to promote angiogenesis and colon cancer progression


ABSTRACT: Oncogenic KRAS (KRAS*) contributes to many cancer hallmarks. In colorectal cancer (CRC), KRAS* has been shown to suppress anti-tumor immunity which promotes tumor metastasis. Here, we show that the protumor actions of KRAS* extend to the adipogenic transformation of fibroblasts into lipid-laden cancer-associated fibroblasts (CAFs), which spur angiogenesis. Mechanistically, KRAS*-mediated activation of the transcription factor CP2 (TFCP2) resulted in TFCP2-mediated transcriptional upregulation of pro-adipogenic factors BMP4 and WNT5B to drive lipid-rich CAF transformation. Functionally, these lipid-rich CAFs promoted tumor growth via their production of vascular endothelial growth factor A (VEGFA). Correspondingly, genetic and pharmacological neutralization of TFCP2 decreased the abundance of lipid-rich CAFs, reduced tumor angiogenesis, and increased survival in an autochthonous KRAS*–driven CRC mouse model. These murine findings mirror translational profiles in human CRC. Thus, KRAS* transforms the stromal cell state to promote tumor angiogenesis and disease progression, providing an actionable therapeutic intervention for KRAS*–driven CRC.

ORGANISM(S): Mus musculus

PROVIDER: GSE229559 | GEO | 2023/09/15

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2020-05-26 | PXD014019 | Pride
2022-03-03 | PXD029507 | Pride
2015-05-08 | E-GEOD-57979 | biostudies-arrayexpress
2019-10-16 | GSE119197 | GEO
2024-05-21 | PXD052413 | JPOST Repository
2023-05-10 | PXD037649 | Pride
2015-05-08 | GSE57979 | GEO
2022-11-01 | GSE162508 | GEO
2018-03-17 | GSE83634 | GEO
2023-09-22 | GSE240232 | GEO